Mode
Text Size
Log in / Sign up

Hypophosphatemia during KRT linked to fewer ventilator-free days in critically ill patients

Hypophosphatemia during KRT linked to fewer ventilator-free days in critically ill patients
Photo by Faustina Okeke / Unsplash
Key Takeaway
Consider monitoring phosphate levels during KRT, as hypophosphatemia is associated with fewer ventilator-free days, but causality is unproven.

This post hoc observational study analyzed data from 1,942 critically ill patients in the STARRT-AKI trial who received kidney replacement therapy (KRT). Among them, 634 developed hypophosphatemia (serum phosphate <0.7 mmol/L) during KRT. The primary outcome was ventilator-free days (VFD) at 28 days.

Incident hypophosphatemia was associated with fewer VFD (beta = 0.91; 95% CI, 0.87-0.95; P < 0.001). Severe hypophosphatemia (<0.5 mmol/L) showed a similar association (beta = 0.87; 95% CI, 0.82-0.93; P < 0.001). The combined outcome of 28-day survival and fewer ventilator days was 27% lower in patients with incident hypophosphatemia and 25% lower in those with severe hypophosphatemia.

No association was found between hypophosphatemia and 90-day mortality or KRT dependence at 90 days. Safety data were not reported.

Key limitations include selection bias and unmeasured confounding. As a post hoc observational analysis, these findings do not establish causality. Clinicians should interpret the association cautiously and consider monitoring phosphate levels during KRT, but randomized trials are needed to confirm any causal relationship.

Study Details

Study typeRct
Sample sizen = 634
EvidenceLevel 2
PublishedMay 2026
View Original Abstract ↓
RATIONALE & OBJECTIVE: Critically ill patients receiving kidney replacement therapy (KRT), especially continuous KRT (CKRT), have a high risk of hypophosphatemia due to extracorporeal losses, which may contribute to muscle weakness and prolonged respiratory failure. This study evaluated the relationship between incident hypophosphatemia and respiratory function in these patients. STUDY DESIGN: Post hoc observational study of STARRT-AKI Trial participants. SETTING & PARTICIPANTS: Eligible trial participants (1) received CKRT >24 hours or intermittent hemodialysis (IHD) or sustained low-efficiency dialysis (SLED) for >1 session, (2) had a serum phosphate level ≥ 0.5 mmol/L on the day of KRT initiation, and (3) had ≥1 serum phosphate measurement during KRT. EXPOSURE: Hypophosphatemia (<0.7 mmol/L) and severe hypophosphatemia (<0.5 mmol/L) during KRT. OUTCOME: Primary outcome was ventilator-free days (VFD) at 28 days of follow-up. Secondary outcomes included mortality and KRT dependence at 90 days. ANALYTICAL APPROACH: A truncated hurdle model was fit to describe clinical characteristics associated with hypophosphatemia. Adjusted analyses of VFD used an inverse probability weighted zero-inflated negative binomial model and a win-ratio analysis. Secondary outcomes were assessed with logistic regression. RESULTS: Of 1,942 trial participants, 634 patients (32.6%) developed hypophosphatemia, and 192 patients (9.9%) developed severe hypophosphatemia. Clinical factors independently associated with incident hypophosphatemia during KRT were female sex, lower body weight, lower serum phosphate levels at KRT initiation, CKRT as the initial KRT modality, and randomization to accelerated KRT initiation. Incident hypophosphatemia and severe hypophosphatemia were associated with fewer VFD at 28 days (β, 0.91 [95% CI, 0.87-0.95] and β, 0.87 [95% CI, 0.82-0.93], respectively; P < 0.001 for both). By win-ratio for any random pair of patients, those with incident hypophosphatemia and severe hypophosphatemia had a 27% and 25% lower likelihood of combined 28-day survival and fewer days on the ventilator, respectively. There was no association between hypophosphatemia and 90-day mortality or KRT dependence. LIMITATIONS: Selection bias and unmeasured confounding. CONCLUSIONS: Incident hypophosphatemia during KRT was independently associated with fewer VFD at 28 days.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.